文献速递消化系统肿瘤

同步与异时性转移性胰腺导管腺癌的疾病播散模式与生存:全国性人群研究

Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based study.
PubMed 文献 · Eur J Cancer · 2025-03-23

基于荷兰癌症登记库(2015-2021年)纳入10,788例同步转移和508例异时性转移性胰腺导管腺癌患者,比较转移模式与总生存。异时性转移患者肝转移较少(48% vs 75%),肺转移(29% vs 21%)和腹膜转移(35% vs 25%)较多;同步转移至肝、肺、淋巴结或多部位的中位OS-M约为异时性同部位转移的一半。

要点

  • 异时性mPAC肝转移较少(48% vs 75%),肺(29% vs 21%)和腹膜(35% vs 25%)转移较多。
  • 异时性mPAC首次转移中位时间13.2个月(IQR 9-23),肝-only 11.5个月,肺-only 28.0个月。
  • 同步转移至肝、肺、淋巴结或多部位的中位OS-M约为异时性同部位转移的一半。

核心结论

  • 全国性人群研究显示,与同步mPAC相比,异时性mPAC较少表现为肝转移,更多转移至肺、腹膜或其他非典型部位。
  • 这些不同的转移模式及其生存差异可能有助于从发现转移灶时改善个体患者的预后评估,并需进一步研究转移发生的生物学机制。

研究设计与样本

  • 从荷兰癌症登记库(2015-2021年)选取同步或异时性转移性胰腺导管腺癌患者。
  • 共纳入10,788例同步mPAC患者和508例异时性mPAC患者。
  • 采用卡方检验比较患者、肿瘤和治疗特征;生存数据从发现转移性疾病起计算(OS-M),采用Kaplan-Meier法和Log-rank检验分析。

主要发现

  • 异时性mPAC首次转移中位时间为13.2个月(IQR 9-23),因转移部位而异:肝-only 11.5个月,肺-only 28.0个月。
  • 与同步mPAC相比,异时性mPAC肝转移较少(48% vs 75%,p < 0.001),肺转移较多(29% vs 21%,p < 0.001),腹膜转移较多(35% vs 25%,p < 0.001)。
  • 同步转移至肝-only、肺-only、淋巴结-only或多部位者,其中位OS-M约为异时性转移至相同部位者的一半。
  • 同步mPAC中骨-only或腹膜-only转移者的中位OS-M与异时性mPAC相当。

局限性

  • 原文结论指出需进一步研究转移发生的生物学机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Despite advances in understanding pancreatic adenocarcinoma, evidence on its metastatic patterns and impact on patient survival remains limited. This study aims to identify patterns of disease dissemination in synchronous versus metachronous metastatic pancreatic adenocarcinoma (mPAC) and their association with overall survival (OS). METHODS: Patients diagnosed with synchronous- or metachronous-mPAC were selected from the Netherlands Cancer Registry (2015-2021). Patient, tumor, and treatment characteristics were compared using Chi-squared tests. Survival data, calculated from detection of metastatic disease (OS-M), were analyzed using Kaplan-Meier and Log-rank tests. RESULTS: Overall, 10,788 patients with synchronous- and 508 with metachronous-mPAC were included. Median time to first metastasis in metachronous-mPAC was 13.2 months (IQR 9-23), varying significantly by metastatic site (liver-only 11.5; lung-only 28.0 months). Compared to synchronous-mPAC, patients with metachronous-mPAC had less liver metastases (48 % versus 75 %, p < 0.001), but more lung (29 % versus 21 %, p < 0.001) and peritoneal (35 % versus 25 %, p < 0.001) metastases. Synchronous metastases to liver-only, lung-only, lymph node-only, or multiple sites at first diagnosis had a median OS-M that was (nearly) half compared to metachronous metastases to the same sites. Bone-only or peritoneum-only metastases in synchronous-mPAC showed a median OS-M comparable to metachronous-mPAC. CONCLUSION: This nationwide population-based study reveals that metachronous-mPAC less commonly presents with liver metastases and more often metastasizes to lung, peritoneum or other atypical sites compared to synchronous-mPAC. These distinct metastatic patterns and their differences in survival may help enhance the prognostic estimation for individual patients from the detection of metastatic disease and warrants further research into the biology underlying metastasis development.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Graus MUJE, van Diepen AE, Josemanders K, et al. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based study. Eur J Cancer. 2025. PMID: 40154212. doi:10.1016/j.ejca.2025.115385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。